California Public Employees Retirement System Increases Holdings in Cambrex Co. (CBM)
California Public Employees Retirement System raised its holdings in shares of Cambrex Co. (NYSE:CBM) by 5.5% in the third quarter, Holdings Channel reports. The institutional investor owned 77,566 shares of the biotechnology company’s stock after acquiring an additional 4,066 shares during the period. California Public Employees Retirement System’s holdings in Cambrex were worth $4,266,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also made changes to their positions in the company. YorkBridge Wealth Partners LLC increased its holdings in Cambrex by 5.2% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 97 shares during the last quarter. Riverhead Capital Management LLC increased its holdings in Cambrex by 90.3% during the second quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,264 shares during the last quarter. Advisor Group Inc. boosted its position in shares of Cambrex by 29.8% in the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 615 shares during the period. Flinton Capital Management LLC boosted its position in shares of Cambrex by 90.9% in the second quarter. Flinton Capital Management LLC now owns 3,570 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 1,700 shares during the period. Finally, Trexquant Investment LP bought a new position in shares of Cambrex in the third quarter worth approximately $209,000.
Separately, Craig Hallum reiterated a “buy” rating and issued a $60.00 price target (down from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $62.33.
Cambrex Co. (NYSE CBM) opened at $52.10 on Thursday. The firm has a market cap of $1,670.00, a P/E ratio of 17.08, a price-to-earnings-growth ratio of 1.23 and a beta of 2.26. Cambrex Co. has a 12-month low of $42.55 and a 12-month high of $62.95.
Cambrex (NYSE:CBM) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.47 by $0.08. The business had revenue of $112.60 million during the quarter, compared to analyst estimates of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The company’s revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.47 earnings per share. equities analysts expect that Cambrex Co. will post 2.97 EPS for the current fiscal year.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.